Contributes to a patient’s overall long-term cumulative radiation exposure long-term cumulative radiation exposure associated with increased cancer risk.Avoid close contact with infants and pregnant women during first 12 hours after administration of Ga 68 dotatate.Short-acting somatostatin analogs can be used up to 24 hr before imaging with Ga 68 dotatate. Image patients with Ga 68 dotatate PET just prior to dosing with long-acting somatostatin analogs. Somatostatin analogs competitively bind to the same somatostatin receptors as Ga 68 dotatate and may affect imaging. Monitor Closely (1)pasireotide decreases effects of gallium Ga 68 dotatate by receptor binding competition. Monitor Closely (1)octreotide decreases effects of gallium Ga 68 dotatate by receptor binding competition. Monitor Closely (1)lanreotide decreases effects of gallium Ga 68 dotatate by receptor binding competition.
Pasireotide decreases effects of gallium Ga 68 dotatate by receptor binding competition. Octreotide decreases effects of gallium Ga 68 dotatate by receptor binding competition. These results strongly suggest that discontinuation of lanreotide injections in the weeks prior to 68Ga-DOTATATE PET examinations is unnecessary and does not compromise nuclear medicine imaging results.Ħ8Ga-DOTATATE Lanreotide Neuroendocrine Tumours PET/CT.Lanreotide decreases effects of gallium Ga 68 dotatate by receptor binding competition. However, these differences were small and not deemed clinically relevant. In contrast, tumour uptake was increased, whereas the uptake in normal organs is decreased, leading to an increased tumour-to-liver ratio. Lanreotide injection prior to 68Ga-DOTATATE PET/CT does not result in decreased tumour uptake. Uptake of 68Ga-DOTATATE in tumour lesions was increased significantly after lanreotide, but decreased significantly in the liver, spleen, and thyroid gland resulting in a higher tumour-to-liver ratio. Of the 34 patients included, 31 were available for analyses in which 190 tumour lesions were measured. Paired T-tests were performed to determine the differences between the scans. All scans were assessed by two blinded nuclear medicine physicians for visual analysis. In each patient 68Ga-DOTATATE uptake (SUV max, mean, peak) was assessed in both tumour lesions and normal tissue. A 68Ga-DOTATATE PET/CT scan was performed on the day before and the day after lanreotide injection.
Thirty-four patients with metastatic and/or unresectable NET and currently on lanreotide therapy for at least 4 months were included in the study. The aim of this study is to prospectively assess the effect of lanreotide use on the uptake of 68Ga-DOTATATE intra-individually 1 day prior to and 1 day post injection of lanreotide. Since therapy and imaging with somatostatin analogues utilize the same receptor, current guidelines recommend withdrawing long-acting somatostatin analogues for 3-4 weeks prior to somatostatin receptor PET imaging. Somatostatin receptor imaging with PET is the standard of care for patients with a neuroendocrine tumour (NET).